Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.67 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.67 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754482 | 1.00 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL13498561 | 0.88 | GNAI3 (0.50) | GNAI3GNAI1GNAO1ITGB3ITGA2B | |
| SCHEMBL16072733 | 0.87 | GNAI3 (0.68) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL16072734 | 0.87 | GNAI3 (0.68) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL10171357 | 0.86 | GNAI3 (0.51) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL764586 | 0.86 | GNAI3 (0.51) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL764605 | 0.82 | GNAI3 (0.74) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL22223257 | 0.82 | GNAI3 (0.74) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL26038984 | 0.82 | GNAI3 (0.68) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL16072731 | 0.81 | GNAI3 (0.59) | GNAI3GNAI1GNAO1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| EP-1708755-B1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | GNAI3 1106/4885GNAI1 1120/4885GNAO1 212/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | GNAI3 1834/4885GNAI1 1692/4885GNAO1 3325/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | GNAI3 1106/4885GNAI1 1120/4885GNAO1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.